abstract |
The present invention is: (a) HDAI; and (b) antimetabolite, In combination for simultaneous, simultaneous, separate or sequential use, in particular for use in the treatment of proliferative diseases, more particularly MDS or AML. The invention also relates to pharmaceutical compositions comprising such combinations and methods of treating MDS or AML in mammals, particularly humans, with such combinations. The invention further relates to a commercial package or product comprising such a combination. |